sharetrader
Page 3 of 919 FirstFirst 12345671353103503 ... LastLast
Results 41 to 60 of 18372
  1. #41
    Member
    Join Date
    Apr 2004
    Location
    , , .
    Posts
    241

    Default

    Cheers Lizard

    You never know,this time next year PEB could actually have three products ready for market.

    The bladder cancer diagnostic,colorectal cancer prognostic,and the melanoma prognostic.

  2. #42
    Share Collector
    Join Date
    Mar 2005
    Location
    Porirua
    Posts
    3,866

    Default

    Genomic Health is working on colon cancer too - and with a slightly bigger budget I would think. Gastric cancer would be the one to nail!

  3. #43
    Advanced Member
    Join Date
    Jul 2004
    Location
    Bolivia.
    Posts
    2,154

    Default

    Just recently aware of this puppy. Any recent thoughts out there?

    Looks risky, but maybe worth a dabble??

  4. #44
    Share Collector
    Join Date
    Mar 2005
    Location
    Porirua
    Posts
    3,866

    Default

    I sold out of PEB. Has been a good hold through the turbulent GFC, but when I bought, I think the market cap was around $12m and it is now about $36m. Still a bit of uncertainty and likely growing pains as they go commercial. The potential may be there, but I'm wary that commercialisation is often a disappointment in the first few years.

    There are so many "cheap" stocks available in NZ at the moment that PEB no longer looks so attractive by comparison.

    Best wishes to holders. I will continue to follow with interest.

  5. #45
    Advanced Member
    Join Date
    Jul 2004
    Location
    Bolivia.
    Posts
    2,154

    Default

    Quote Originally Posted by Lizard View Post
    I sold out of PEB. Has been a good hold through the turbulent GFC, but when I bought, I think the market cap was around $12m and it is now about $36m. Still a bit of uncertainty and likely growing pains as they go commercial. The potential may be there, but I'm wary that commercialisation is often a disappointment in the first few years.

    There are so many "cheap" stocks available in NZ at the moment that PEB no longer looks so attractive by comparison.

    Best wishes to holders. I will continue to follow with interest.
    I have been watching since my last post - at 11c. Never bought in and obviously have rued this. The price strengthened up to about 25c, and has recently dropped back to about 17c.

    But the big jump Monday/Tuesday was probably caused by this and a lack of liquidity.

    http://www.stuff.co.nz/sunday-star-t...e-in-7b-market

    Still interested if the price is right. Know one person invloved in the company and fairly serious person, who I would rate.

  6. #46
    Adventurer Silverlight's Avatar
    Join Date
    Dec 2009
    Posts
    513
    ~ * ~ De Peones a Reinas ~ * ~

  7. #47
    Junior Member
    Join Date
    Jan 2010
    Posts
    26

    Default

    ____________________________________
    Last edited by rpcas; 14-04-2011 at 09:35 PM.

  8. #48
    Adventurer Silverlight's Avatar
    Join Date
    Dec 2009
    Posts
    513

    Default

    Just aim to get in at an average price then.

    If you have $10k, buy 2k @ 35 cents, put 2k on the market at the best bid, you might pick them up for 30 -33 cents.

    And wait for the trial results, if they are negative the price might go back to 15 -20 cents, and you only lose out on the 4k you invested, and you can buy another 2k at 15-20 cents.

    If the the results are positive, and price goes up, you have a little skin in the game, and you accumulate more on the way up.


    This is all based on the fact that you think long term the stock is fundamenatlly sound investment for your risk level.
    ~ * ~ De Peones a Reinas ~ * ~

  9. #49
    Junior Member
    Join Date
    Jan 2010
    Posts
    26

    Default

    ______________________________
    Last edited by rpcas; 14-04-2011 at 09:35 PM.

  10. #50
    Adventurer Silverlight's Avatar
    Join Date
    Dec 2009
    Posts
    513

    Default

    Commercialisation of Pacific Edge's Bladder Detection Test

    https://www.i-search.nzx.com/blobs/N...000-113259.pdf
    ~ * ~ De Peones a Reinas ~ * ~

  11. #51
    Adventurer Silverlight's Avatar
    Join Date
    Dec 2009
    Posts
    513

    Default

    Pacific Edge announces Cxbladder performance at the Australian and New Zealand urologists scientific meeting in Perth, Australia.

    22 February 2010

    Pacific Edge announced the clinical trial performance of the Cxbladder, test in Perth on Monday 22nd of February. Peter Davidson, a renowned New Zealand urologist and the lead clinical investigator in this research, presented the scientific performance of Cxbladder to the Australasian urologists and medical professionals at their Annual Scientific Meeting. The scientific meeting hosted 600 delegates with urologists from New Zealand, Australia, US, Singapore, South Africa, United Kingdom, Ireland, Indonesia, Hong Kong, Malaysia and Papua New Guinea.

    The Company’s bladder cancer diagnostic technology, Cxbladder, enables the early detection of bladder cancer from a small volume of urine. The presentation in Perth reported on the performance of Cxbladder, the new commercial product developed from the clinical trial data. Cxbladder showed an approximate overall sensitivity that was 30% better than urine cytology and 40% better than the competitor test NMP22. Its performance was most notable for the detection of tumours of high grade, and middle and late stage, where it correctly identified greater than 96% of cases with 85% specificity. These tumours are of particular concern to urologists and the tests high performance provides an opportunity to improve patient outcome and lower overall costs of treatment.

    The Company, as part of its roll-out in the US and Europe, has plans in place for further studies that will have the dual purpose of providing further validation data and also engaging specific key medical and urological opinion leaders who will be vital to a successful launch in new markets.

    This non-invasive test is expected to provide general practitioners and urologists with a quick, cost effective and accurate measure of the presence of the cancer and provides urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy. After additional clinical testing, Cxbladder is also anticipated to be used for monitoring patients for recurrence following treatment.

    Pacific Edge completed recruitment of patients for the bladder cancer clinical trial in late 2009 and analysis of the data was completed in February. The data analysis on almost 500 patients from NZ/Australia shows that the Company’s bladder cancer test has met its clinical end points and performs significantly better than all of the benchmark tests.

    Bladder cancer is one of the most common cancers in Western society. In Australasia, bladder cancer is the 5th most common cancer among men and the eighth most common cancer overall. On a global basis there are 365,000 new cases annually and 47,000 deaths.

    Bladder cancer has the highest total medical costs of any cancer driven in part by the very high recurrence rate (50-90%), with approximately 15-30% of these recurring as later stage tumours. The surveillance of patients who have been diagnosed with bladder cancer extends for at least five years from the time of first diagnosis. Surveillance is currently carried out by urologists using invasive cystoscopy often accompanied by one or more cytologies. The Company’s test is designed to replace cytology and to also be used as an adjunct to cystoscopy. Its use is predicted to not only improve the quality of surveillance but also lead to a decrease in the frequency of cystoscopies.

    The Company is progressing the commercialisation of this product to Australasian urologists through its Dunedin based laboratory. The Company is currently developing its commercial laboratory to provide a dedicated service and would expect that this will be completed within the next few months and the test offered commercially in May 2010.

    Commercialisation of Cxbladder is planned to follow-on in Singapore, USA and Europe by providing services to physicians and urologists through a centralised service laboratory strategy in each geography. Pacific Edge anticipates partnering in several of these locations using the services model being developed in the Australasian market and negotiations are currently underway with potential commercial partners in the US, Europe and Australasia.

    The Company has recently been awarded patents in New Zealand and Singapore for its bladder cancer diagnostic technology and the Company anticipates the issue of these patents in other targeted countries to follow over the next 12 to 24 months.

    Pacific Edge Biotechnology Ltd, (PEB), is a Dunedin based biomedical company developing and commercialising technology for cancer detection and management.
    ~ * ~ De Peones a Reinas ~ * ~

  12. #52
    Member
    Join Date
    Mar 2006
    Location
    , , New Zealand.
    Posts
    145

    Default

    even dropped back to 25c this has made as much as resteraunt brands and feels like a bomb about to go off.
    Make NZ good and great, God defend NZ.

  13. #53
    Adventurer Silverlight's Avatar
    Join Date
    Dec 2009
    Posts
    513

    Default

    NZX Release Pacific Edge (PEB)

    Pacific Edge advises the successful completion of the European clinical trial of our prognostic gene signature for colorectal cancer. This is a significant commercial milestone for the Company. The clinical trial results for Pacific Edge’s gene signature will be presented at the annual scientific meeting of the American Society of Clinical Oncology (ASCO) by our European licensee in early June in Chicago. Pacific Edge’s colorectal cancer prognostic gene signature is the second commercial product for the Company and it joins the Company’s recently launched bladder cancer detection test Cxbladder.

    Europe is the second largest healthcare market in the world after the US, representing approximately 30% of global health care spending.

    Colorectal cancer has second highest incidence of all cancers creating a large impact worldwide with over 1.1 million new cases annually. Colorectal cancer has a particularly high incidence in Japan, Australia, New Zealand, Europe and North America. It is anticipated that this year over 530,000 people globally will die from the disease.

    This new product for the prognosis of colorectal cancer is targeted to meet a large unmet clinical need for patients diagnosed with colorectal cancer. Pacific Edge’s prognostic gene signature identifies patients with stage II or III colorectal cancer whose disease is aggressive, likely to recur after surgery and who would benefit from additional treatment. The identification of those patients at greatest risk represents a new tool for clinicians and effective use of this tool by clinicians could be expected to lead to better treatment and more lives saved.

    Pacific Edge’s colorectal cancer prognostic gene signature is the second commercial product for the Company and it joins the Company’s recently launched bladder cancer detection test Cxbladder. Cxbladder is a fast, accurate, non-invasive assay that accurately measures the activity of five genes from a small sample of the patients’ urine to diagnose bladder cancer.

    Pacific Edge is a biomedical company specialising in the development and commercialisation of diagnostics and prognostics for cancer. The Company is also actively working on the research and development of products for gastric cancer, endometrial cancer and melanoma.
    ~ * ~ De Peones a Reinas ~ * ~

  14. #54
    Banned
    Join Date
    Jan 2002
    Location
    hastings, , New Zealand.
    Posts
    650

    Default

    Thanks for finding the thread .. Phaedrus.

    Will be interesting if this news (released at close of market yesterday) moves the share price.....on the basis of bouncing of the support at 20c four times. ( in the last several weeks). and the increased volumn .. I purchased on Monday and last week at 22c.
    Would expect a price spike... but the markets are currently not buoyant. 6 hours will tell.

  15. #55
    Banned
    Join Date
    Jan 2002
    Location
    hastings, , New Zealand.
    Posts
    650

    Default

    Closed at 32c ..up over 50% in the last 10 days...............Would a real chartist (as opposed to a rank amateur like myself) be prepared to voice a opinion .on where from now............ thanks.

  16. #56
    Adventurer Silverlight's Avatar
    Join Date
    Dec 2009
    Posts
    513

    Default

    Pacific Edge Announces Successful Completion of Colorectal Cancer Prognostic Clinical Trial

    Clinical Results Presented Today at ASCO 2010



    CHICAGO, IL (June 4, 2010): Pacific Edge (PEB) a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately. PEB’s European licensee, Signature Diagnostics (SDX) completed the clinical trial and will present the results at the annual scientific meeting of the American Society of Clinical Oncology in Chicago on the 4th of June.

    Chief Executive Officer David Darling stated that the conclusion of the European clinical trial, was a significant commercial milestone for Pacific Edge. “This prognostic gene signature for colorectal cancer is our second commercial product, and joins our bladder cancer diagnostic assay, Cxbladder™. Cxbladder™ is a fast, non-invasive assay that measures the activity of five genes from a small sample of the patient’s urine to accurately diagnose bladder cancer.”

    Pacific Edge Chief Scientific Officer, Parry Guilford commented that the company’s prognostic gene signature will meet a large unmet clinical need for patients diagnosed with stage II and stage III colorectal cancer. “Our prognostic gene signature identifies patients with stage II or III colorectal cancer whose disease is aggressive, likely to recur after surgery, and who would benefit from additional therapy”.

    Pacific Edge granted a European exclusive licence for its new cutting-edge prognostic gene signature for colorectal cancer to SDX in late 2006 with commercialisation pending a sucessful completion of the clinical trial. Europe is the second largest healthcare market in the world after the United States and represents around 30 per cent of global health care spending.

    Colorectal cancer has the second highest incidence of all cancers in the world, with over 1.1 million new cases diagnosed annually. It has a particularly high incidence in Japan, Australia, New Zealand, Europe and North America. This year more than 530,000 people around the world are expected to die from the disease.
    ~ * ~ De Peones a Reinas ~ * ~

  17. #57
    Member
    Join Date
    Dec 2004
    Location
    Auckland, , New Zealand.
    Posts
    50

    Default

    Did any one go to the AGM or have news from the AGM

  18. #58
    Member
    Join Date
    Apr 2004
    Location
    , , .
    Posts
    241

    Default

    I did'nt get to the AGM but there will probably be something about it in the Otago Daily Times tomorrow or Monday.

  19. #59
    Banned
    Join Date
    Jan 2002
    Location
    hastings, , New Zealand.
    Posts
    650

    Default

    Thanks for that update Hancocks...was tempted to go down.. but living in Hastings...
    Couple of questions if I may..

    A/ From a commercial.. point of view.. Did you get the vibe.. that the products would make the company profitable in the next year or so.

    B/ Any hint of new product/tests ..or value adding in the next 6 months to a year.

    Thanks for that.

    Cheers.

  20. #60
    Member
    Join Date
    Apr 2007
    Location
    , , .
    Posts
    390

    Default

    If they believe they could be cash positive, and it comes true, it might be time to get in.

Tags for this Thread

Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •